JSKN016 + eribulin

JSKN016 + eribulin is a combination drug regimen under investigation for use in patients with inoperable, locally advanced, or metastatic HER2-negative breast cancer, including both hormone receptor-positive (HR+HER2-negative) and triple-negative breast cancer (TNBC)[1]. **JSKN016** is an investigational agent whose precise mechanism of action and structural details are not publicly described in indexed sources, but it is being evaluated in clinical trials in combination with chemotherapy or immunotherapy backbones. **Eribulin** is a synthetic analog of halichondrin B, functioning as a microtubule dynamics inhibitor that leads to G2/M cell cycle arrest and apoptosis in tumor cells. The combination aims to capitalize on distinct mechanisms: eribulin’s disruption of microtubule dynamics and JSKN016’s (putative) novel, complementary or synergistic anticancer pathway(s)[1].